Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05757102 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
A Phase 3 study of Asthma, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 292
- Enrollment target
- 20
- Study locations
NCT05757102: Recruiting Phase 3 study of Asthma, sponsored by GlaxoSmithKline.
NCT05757102 is a Phase 3 study of Asthma that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 292 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05757102, a Phase 3 study of Asthma, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 292 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.
Primary Outcome
FEV1 will be measured using spirometry.
Conditions Studied
Interventions
- DRUG FF/UMEC/VI
- DEVICE ELLIPTA
- DRUG FF/VI
Study Locations (20)
California
- GSK Investigational Site - Bakersfield
- GSK Investigational Site - Huntington Beach
- GSK Investigational Site - Mission Viejo
- GSK Investigational Site - Rolling Hills Estates
- GSK Investigational Site - Walnut Creek
Florida
- GSK Investigational Site - Aventura
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami
Alabama
- GSK Investigational Site - Birmingham
- GSK Investigational Site - Mobile
Arizona
- GSK Investigational Site - Paradise Valley
Colorado
- GSK Investigational Site - Colorado Springs
Georgia
- GSK Investigational Site - Savannah
Illinois
- GSK Investigational Site - Normal
Kentucky
- GSK Investigational Site - Owensboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2023-04-25 |
| Est. Completion | 2027-01-15 |
| Phase | Phase 3 |
What NCT05757102 shows while recruiting
NCT05757102 is an interventional study that assigns participants to a tested intervention. The registered 292 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which FF/UMEC/VI is the first listed.
NCT05757102 names 20 study sites across 12 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT05757102 about?
NCT05757102 is a clinical study titled "A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma". The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.
What is the current status of trial NCT05757102?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 292 participants. The study started on 2023-04-25. Estimated completion is 2027-01-15.
What conditions does trial NCT05757102 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT05757102?
The interventions under investigation include: FF/UMEC/VI (DRUG), ELLIPTA (DEVICE), FF/VI (DRUG).
Who is sponsoring clinical trial NCT05757102?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05757102 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05757102's enrollment target sits among peer trials
292 132nd of 374 higher than 243 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
-
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04429542 · 292 participants · Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- NCT05406622 · 292 participants · NA
MOTIV BTK Randomized Controlled Trial
- NCT06569667 · 292 participants · NA
Using AI and Peer Coaching to Address Racial Disparities Among People Who Use Opioids
- NCT06724016 · 292 participants · Phase 1
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI